Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
Anticancer Res. 2010 Jul;30(7):2985-90.
The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer.
We comprised 110 patients with stage IIIB or IV non-small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates.
On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly.
Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
代谢拮抗剂 S-1 抑制胸苷酸合成酶的作用类似于培美曲塞，但作用机制不同。S-1 的抗肿瘤活性是否取决于组织学类型尚不清楚。我们分析了先前未经治疗的晚期非小细胞肺癌患者接受顺铂和 S-1 联合治疗的 2 项 II 期临床试验的汇总数据。
我们纳入了 110 名 IIIB 期或 IV 期非小细胞肺癌患者。进行了单变量和多变量分析，以确定组织学类型对无进展生存期和缓解率的影响。
根据组织学类型进行汇总分析，鳞状细胞癌患者的中位无进展生存期为 3.8 个月，非鳞状细胞癌患者为 4.4 个月。两种分析均显示无进展生存期和缓解率无显著差异。
与分子靶向药物和培美曲塞不同，顺铂和 S-1 的联合用药可能与组织学类型无关。
